Antibiotics - MRSA - MD Browse

Antibiotics – MRSA

Speciality
Spotlight

Clinical Pharmacology

Antibiotics
–
MRSA

Kathryn
Senior

FDA approves first drug in new class of antibiotics

The
Lancet
2000; 29 April, 355: 1523.

One of the problems of drug resistant bacterial
infections is MRSA (Methicillin Resistant Staphylococcus Aureus)
which has become a most dangerous infection.
This bacteria has now become Vancomycin-resistant.

A
new class of antibiotic has now been approved.
The antibiotic named Zyvox (Linezolid) has novel mode of
action, it blocks bacterial protein production by disrupting the
binding of bacterial ribosome.
It is hoped that this will make the treatment of MRSA
infection simpler.

Speciality Spotlight

Clinical Pharmacology

Antibiotics – MRSA

Kathryn Senior
FDA approves first drug in new class of antibiotics
The Lancet 2000; 29 April, 355: 1523.

One of the problems of drug resistant bacterial infections is MRSA (Methicillin Resistant Staphylococcus Aureus) which has become a most dangerous infection. This bacteria has now become Vancomycin-resistant.

A new class of antibiotic has now been approved. The antibiotic named Zyvox (Linezolid) has novel mode of action, it blocks bacterial protein production by disrupting the binding of bacterial ribosome. It is hoped that this will make the treatment of MRSA infection simpler.

By Oleg Iuchis|2022-07-20T16:44:04+00:00July 20, 2022|Uncategorized|Comments Off

About the Author: Oleg Iuchis

It is a long established fact that the read will been distracted by there readable an important content. It is a long established fact that the read will been distracted.

It is a long established fact that the read will been distracted by there readable an important content. It is a long established fact that the read will been distracted.